Cormorant Asset Management »

Vyne Therapeutics shares owned by Cormorant Asset Management

Quarter-by-quarter ownership of Vyne Therapeutics (VYNE) shares owned by Cormorant Asset Management from 13F filings

Historical chart of Cormorant Asset Management investment in Vyne Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Vyne Therapeutics held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Vyne Therapeutics by Cormorant Asset Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $2.7M 1.4M 1.97
2024-03-31 $4.3M 1.4M 3.07
2023-12-31 $3.2M 1.4M 2.33

More positions owned by Cormorant Asset Management

Moonlake Immunotherapeutics Class A Ord (MLTX)
Corbus Pharmaceuticals Hldgs Com New (CRBP)
Arcellx Common Stock (ACLX)
Vaxcyte (PCVX)
Longboard Pharmaceuticals In (LBPH)
Eyepoint Pharmaceuticals Com New (EYPT)
Rapport Therapeutics (RAPP)
Crinetics Pharmaceuticals In (CRNX)
Edgewise Therapeutics (EWTX)
Merus N V (MRUS)
Bridgebio Pharma (BBIO)
Insmed Com Par $.01 (INSM)
Newamsterdam Pharma Company Ordinary Shares (NAMS)
Janux Therapeutics (JANX)
Axsome Therapeutics (AXSM)

View all positions for Cormorant Asset Management

Top funds holding Vyne Therapeutics

Eventide Asset Management
Cormorant Asset Management
Citadel Advisors
DSC Advisors
Silverarc Capital Management
Palo Alto Investors
Vanguard Group
Exome Asset Management
Parkman Healthcare Partners
AlphaCentric Advisors
Schonfeld Strategic Advisors
Geode Capital Management
Renaissance Technologies
BlackRock
Susquehanna International

View all funds holding Vyne Therapeutics